ArticleFrontiers in cell and developmental biology2025
Risk factors and prognosis of poor graft function after allogeneic hematopoietic stem cell transplantation in pediatric: a retrospective study.
Article in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Poor graft function (PGF) represents a serious and potentially life-threatening complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT); however, its etiological risk factors and prognostic implications remain inadequately defined within pediatric populations. Methods: A retrospective cohort study was conducted on 175 pediatric patients undergoing allo-HSCT between 30 June 2018, and 31 December 2022. Patients were stratified into PGF (n = 30) and good graft function (GGF, n = 145) groups. Multivariate logistic regression identified risk factors for PGF, while Cox proportional hazards models evaluated mortality-associated variables. Survival outcomes were analyzed using Kaplan-Meier curves. Results: Key findings encompass: (1) PGF Risk Factors: Multivariable analysis identified four independent predictors of PGF: age ≥10 years at transplantation (OR = 29.27, 95%CI: 5.70-150.21, P < 0.001), HLA mismatch (OR = 4.11, 95%CI: 1.45-11.65, P = 0.008), cytomegalovirus (CMV) infection (OR = 7.64, 95%CI: 2.31-25.21, P = 0.001), and BK virus (BKV) infection (OR = 12.22, 95%CI: 2.49-59.89, P = 0.002); The model's predictive performance by ROC analysis yielded an AUC of 0.886 (95%CI: 0.83-0.94; P < 0.001). (2) Survival Analysis: the 4-year overall survival (OS) was profoundly inferior in the PGF cohort compared to the GGF cohort (49.4% ± 10.3% vs. 90.2% ± 2.5%, P < 0.001). (3) Predictors of Mortality: Cox regression identified PGF (HR = 2.39, 95%CI: 1.02-5.59, P = 0.044), acute graft-versus-host disease (grade I/II, HR = 3.43, 95%CI: 1.29-9.15, P = 0.014; grade III/IV, HR = 8.92, 95%CI: 3.19-24.96, P < 0.001), hemorrhagic cystitis (HR = 3.18, 95%CI: 1.37-7.39, P = 0.007), and severe pneumonia (HR = 4.42, 95%CI: 1.92-10.19, P < 0.001) as independent predictors of early mortality. Conclusion: Age ≥10 years at transplantation, HLA mismatch, CMV infection, or BK viremia identifies a high-risk cohort of pediatric allo-HSCT recipients who require intensified monitoring for PGF, underscoring an urgent need for effective preventive and therapeutic interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.